A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Navitoclax (Primary) ; Bendamustine; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms NAVIGATE
- Sponsors Genentech
- 31 May 2013 Planned End Date changed from 1 May 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Oct 2011 Additional locations added as reported by ClinicalTrials.gov.